Sheng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sheng Zhang has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
Ren Wang
Affiliated Cancer Hospital and Institute, Guangzhou Medical University, Guangzhou 511436, Guangdong, China
3 shared publications- Arabela A. Grigorescu
Keck Biophysics Facility Northwestern University 2220 Campus Drive Evanston IL 60208 USA
2 shared publications Bakhtiyor Yakubov
2 shared publicationsConstandina Arvanitis
2 shared publications- Daniela Matei
Department of Obstetrics and Gynecology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611, USA
2 shared publications - Gary E. Schiltz
Department of Chemistry, Northwestern University, Evanston, IL 60208, USA
2 shared publications
Latest Publications
- Open Access
- 2 December 2025
- Vol. 8
Osimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies
Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors, particularly osimertinib. Although recent clinical trials have established osimertinib as effective treatment across many stages of EGFR-mutant NSCLC, the inevitable emergence of acquired resistance poses a major therapeutic challenge despite the substantial clinical benefit. Understanding the mechanisms of osimertinib acquired resistance is urgently needed to identify effective strategies to overcome it. Resistance to osimertinib including on-target mechanisms such as novel EGFR secondary mutation, off-target mechanisms such as mesenchymal-epithelial transition or human EGFR 2 amplification, mutations in downstream signaling molecules, and oncogenic fusions, and the Histological transformations (such as epithelial-mesenchymal transition, squamous cell carcinoma, or small cell lung cancer) have been well described. This review summarizes the mechanisms and clinical significance of osimertinib-acquired resistance in recent years, as well as new clinical treatments. It is expected to provide valuable insights and potential new strategies for the clinical treatment of EGFR-mutated NSCLC patients with osimertinib resistance.
- 2 December 2025
- Vol. 8
Open AccessOsimertinib acquired resistance among patients with EGFR-mutated NSCLC: from molecular mechanisms to clinical therapeutic strategies
Non-small-cell lung cancer (NSCLC) remains the leading cause of global cancer-related mortality. NSCLC patients with epidermal growth factor receptor (EGFR) mutations benefit substantially from treatment with EGFR tyrosine kinase inhibitors, particularly osimertinib. Although recent clinical trials have established osimertinib as effective treatment across many stages of EGFR-mutant NSCLC, the inevitable emergence of acquired resistance poses a major therapeutic challenge despite the substantial clinical benefit. Understanding the mechanisms of osimertinib acquired resistance is urgently needed to identify effective strategies to overcome it. Resistance to osimertinib including on-target mechanisms such as novel EGFR secondary mutation, off-target mechanisms such as mesenchymal-epithelial transition or human EGFR 2 amplification, mutations in downstream signaling molecules, and oncogenic fusions, and the Histological transformations (such as epithelial-mesenchymal transition, squamous cell carcinoma, or small cell lung cancer) have been well described. This review summarizes the mechanisms and clinical significance of osimertinib-acquired resistance in recent years, as well as new clinical treatments. It is expected to provide valuable insights and potential new strategies for the clinical treatment of EGFR-mutated NSCLC patients with osimertinib resistance.
- Open Access
- 6 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1472361
Recent advances in extracellular matrix manipulation for kidney organoid research
The kidney plays a crucial role in maintaining the body’s microenvironment homeostasis. However, current treatment options and therapeutic agents for chronic kidney disease (CKD) are limited. Fortunately, the advent of kidney organoids has introduced a novel in vitro model for studying kidney diseases and drug screening. Despite significant efforts has been leveraged to mimic the spatial-temporal dynamics of fetal renal development in various types of kidney organoids, there is still a discrepancy in cell types and maturity compared to native kidney tissue. The extracellular matrix (ECM) plays a crucial role in regulating cellular signaling, which ultimately affects cell fate decision. As a result, ECM can refine the microenvironment of organoids, promoting their efficient differentiation and maturation. This review examines the existing techniques for culturing kidney organoids, evaluates the strengths and weaknesses of various types of kidney organoids, and assesses the advancements and limitations associated with the utilization of the ECM in kidney organoid culture. Additionally, it presents a discussion on constructing specific physiological and pathological microenvironments using decellularized extracellular matrix during certain developmental stages or disease occurrences, aiding the development of kidney organoids and disease models.
- 6 November 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1472361
Open AccessRecent advances in extracellular matrix manipulation for kidney organoid research
The kidney plays a crucial role in maintaining the body’s microenvironment homeostasis. However, current treatment options and therapeutic agents for chronic kidney disease (CKD) are limited. Fortunately, the advent of kidney organoids has introduced a novel in vitro model for studying kidney diseases and drug screening. Despite significant efforts has been leveraged to mimic the spatial-temporal dynamics of fetal renal development in various types of kidney organoids, there is still a discrepancy in cell types and maturity compared to native kidney tissue. The extracellular matrix (ECM) plays a crucial role in regulating cellular signaling, which ultimately affects cell fate decision. As a result, ECM can refine the microenvironment of organoids, promoting their efficient differentiation and maturation. This review examines the existing techniques for culturing kidney organoids, evaluates the strengths and weaknesses of various types of kidney organoids, and assesses the advancements and limitations associated with the utilization of the ECM in kidney organoid culture. Additionally, it presents a discussion on constructing specific physiological and pathological microenvironments using decellularized extracellular matrix during certain developmental stages or disease occurrences, aiding the development of kidney organoids and disease models.
- Open Access
- 3 July 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1417306
Recent progress of exosomal lncRNA/circRNA–miRNA–mRNA axis in lung cancer: implication for clinical application
Lung cancer is the leading cause of death among malignant tumors in the world. High lung cancer mortality rate is due to most of patients diagnosed at advanced stage. The Liquid biopsy of lung cancer have received recent interest for early diagnosis. One of the components of liquid biopsy is the exosome. The exosome cargos non-coding-RNAs, especially long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs). The lung cancer derived exosomal non-coding RNAs play the pivotal roles of lung cancer in carcinogenesis, diagnosis, therapy, drug resistance and prognosis of lung cancer. Given ceRNA (competitive endogenous RNA) mechanism, lncRNA or circRNA can act as ceRNA to compete to bind miRNAs and alter the expression of the targeted mRNA, contributing to the development and progression of lung cancer. The current research progress of the roles of the exosomal non-coding-RNAs and the interplay of ceRNAs and miRNAs in mediated lung cancer is illustrated in this article. Hence, we presented an experimentally validated lung cancer derived exosomal non-coding RNAs-regulated target gene axis from already existed evidence in lung cancer. Then LncRNA/circRNA-miRNA-mRNA axis may be a potential target for lung cancer treatment and has great potential in the diagnosis and prognosis of lung cancer.
- 3 July 2024
- Published by Frontiers Media SA in Frontiers in Molecular Biosciences
- Vol. 11, 1417306
Open AccessRecent progress of exosomal lncRNA/circRNA–miRNA–mRNA axis in lung cancer: implication for clinical application
Lung cancer is the leading cause of death among malignant tumors in the world. High lung cancer mortality rate is due to most of patients diagnosed at advanced stage. The Liquid biopsy of lung cancer have received recent interest for early diagnosis. One of the components of liquid biopsy is the exosome. The exosome cargos non-coding-RNAs, especially long non-coding RNAs (lncRNAs), circular RNAs (circRNAs), and microRNAs (miRNAs). The lung cancer derived exosomal non-coding RNAs play the pivotal roles of lung cancer in carcinogenesis, diagnosis, therapy, drug resistance and prognosis of lung cancer. Given ceRNA (competitive endogenous RNA) mechanism, lncRNA or circRNA can act as ceRNA to compete to bind miRNAs and alter the expression of the targeted mRNA, contributing to the development and progression of lung cancer. The current research progress of the roles of the exosomal non-coding-RNAs and the interplay of ceRNAs and miRNAs in mediated lung cancer is illustrated in this article. Hence, we presented an experimentally validated lung cancer derived exosomal non-coding RNAs-regulated target gene axis from already existed evidence in lung cancer. Then LncRNA/circRNA-miRNA-mRNA axis may be a potential target for lung cancer treatment and has great potential in the diagnosis and prognosis of lung cancer.
- 16 October 2023
- Published by Springer Nature in Aquaculture International
- Vol. 32 (3) , 2841-2863
Hormonal regulation changes in shrimp infected with Enterocytozoon hepatopenaei: a transcriptomic analysis
- 16 October 2023
- Published by Springer Nature in Aquaculture International
- Vol. 32 (3) , 2841-2863
Hormonal regulation changes in shrimp infected with Enterocytozoon hepatopenaei: a transcriptomic analysis
- Open Access
- 11 September 2023
- Published by Springer Nature in Scientific Data
- Vol. 10 (1) , 1-12
Comparison of miRNA transcriptome of exosomes in three categories of somatic cells with derived iPSCs
Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) through epigenetic manipulation. While the essential role of miRNA in reprogramming and maintaining pluripotency is well studied, little is known about the functions of miRNA from exosomes in this context. To fill this research gap,we comprehensively obtained the 17 sets of cellular mRNA transcriptomic data with 3.93 × 1010 bp raw reads and 18 sets of exosomal miRNA transcriptomic data with 2.83 × 107 bp raw reads from three categories of human somatic cells: peripheral blood mononuclear cells (PBMCs), skin fibroblasts(SFs) and urine cells (UCs), along with their derived iPSCs. Additionally, differentially expressed molecules of each category were identified and used to perform gene set enrichment analysis. Our study provides sets of comparative transcriptomic data of cellular mRNA and exosomal miRNA from three categories of human tissue with three individual biological controls in studies of iPSCs generation, which will contribute to a better understanding of donor cell variation in functional epigenetic regulation and differentiation bias in iPSCs.
- 11 September 2023
- Published by Springer Nature in Scientific Data
- Vol. 10 (1) , 1-12
Open AccessComparison of miRNA transcriptome of exosomes in three categories of somatic cells with derived iPSCs
Somatic cells can be reprogrammed into induced pluripotent stem cells (iPSCs) through epigenetic manipulation. While the essential role of miRNA in reprogramming and maintaining pluripotency is well studied, little is known about the functions of miRNA from exosomes in this context. To fill this research gap,we comprehensively obtained the 17 sets of cellular mRNA transcriptomic data with 3.93 × 1010 bp raw reads and 18 sets of exosomal miRNA transcriptomic data with 2.83 × 107 bp raw reads from three categories of human somatic cells: peripheral blood mononuclear cells (PBMCs), skin fibroblasts(SFs) and urine cells (UCs), along with their derived iPSCs. Additionally, differentially expressed molecules of each category were identified and used to perform gene set enrichment analysis. Our study provides sets of comparative transcriptomic data of cellular mRNA and exosomal miRNA from three categories of human tissue with three individual biological controls in studies of iPSCs generation, which will contribute to a better understanding of donor cell variation in functional epigenetic regulation and differentiation bias in iPSCs.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin
Materials, methods; Figure S1. 1H NMR spectrum of MT-1; Figure S2. 1H NMR spectrum of MT-2; Figure S3. 1H NMR spectrum of MT-3; Figure S4. 1H NMR spectrum of MT-4; Figure S5. 1H NMR spectrum of MT-5; Figure S6. 1H NMR spectrum of MT-6; Figure S7. Enthalpy kinetics of MT-4 -TG2 interaction as measured by Isothermal Titration Calorimetry (ITC); Figure S8. Effects of TG-53 and MT-4 on TGase activity; Figure S9. TIRF analysis of β1 integrin receptors distribution upon cell treatment with SMIs at the indicated concentrations and adhesion onto FN coated plates; Figure S10. Flow cytometry analysis of integrin β1 plasma membrane expression; Figure S11. Dose response effects induced by TG2-FN inhibitors on FAK phosphorylation; Figure S12. Experimental design for in vivo assay testing the activity of MT4; Figure S13. Cell cycle distribution and apoptosis of OVCAR5 cells primed with MT-4 or TG53 for 72 hours before treatment with paclitaxel (PTX).
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin
Materials, methods; Figure S1. 1H NMR spectrum of MT-1; Figure S2. 1H NMR spectrum of MT-2; Figure S3. 1H NMR spectrum of MT-3; Figure S4. 1H NMR spectrum of MT-4; Figure S5. 1H NMR spectrum of MT-5; Figure S6. 1H NMR spectrum of MT-6; Figure S7. Enthalpy kinetics of MT-4 -TG2 interaction as measured by Isothermal Titration Calorimetry (ITC); Figure S8. Effects of TG-53 and MT-4 on TGase activity; Figure S9. TIRF analysis of β1 integrin receptors distribution upon cell treatment with SMIs at the indicated concentrations and adhesion onto FN coated plates; Figure S10. Flow cytometry analysis of integrin β1 plasma membrane expression; Figure S11. Dose response effects induced by TG2-FN inhibitors on FAK phosphorylation; Figure S12. Experimental design for in vivo assay testing the activity of MT4; Figure S13. Cell cycle distribution and apoptosis of OVCAR5 cells primed with MT-4 or TG53 for 72 hours before treatment with paclitaxel (PTX).
- Open Access
- 28 April 2017
- Published by Wiley in Brain and Behavior
- Vol. 7 (6) , e00689
Cerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design
Introduction: The risk of recurrent stroke is high in patients with intracranial atherosclerotic stenosis (ICAS). Statin use has been demonstrated to decrease the incidence of stroke by reducing atherosclerotic plaque burden. However, its effect on the hemodynamic situation and cerebral perfusion status has not yet been validated. With the use of computed tomography perfusion (CTP), we aim to evaluate the impact of Rosuvastatin on cerebral hemodynamic changes, as well as the downstream perfusion.Method: Cerebral bood flow evaluation of intensive rosuvastatin therapy in patients with intracranial arterial atherosclerotic stenosis (CEIRIS) is a single‐center, prospective, randomized, parallel‐group, and open‐label trial, and it will include 50 participants as estimated. Patients with moderate to severe (50%–99%) ICAS are randomized 1:1 to 10 mg/day or 20 mg/day Rosuvastatin and followed every 13 weeks until 52 weeks. The primary outcome for the trial is the change in the relative regional cerebral blood flow evaluated by CTP after 52 weeks of Rosuvastatin treatment. The secondary outcomes are cerebral blood volume, change in the degree of stenosis of the target vessel and lipid parameters.Conclusion: The CEIRIS trial about the effects of statin on the temporal hemodynamic progression of ICAS may extend our understanding of the basic pathophysiology and mechanisms of stroke in ICAS patients.
- 28 April 2017
- Published by Wiley in Brain and Behavior
- Vol. 7 (6) , e00689
Open AccessCerebral blood flow evaluation of intensive rosuvastatin therapy in stroke/transient ischemic attack patients with intracranial arterial atherosclerotic stenosis study: Rationale and design
Introduction: The risk of recurrent stroke is high in patients with intracranial atherosclerotic stenosis (ICAS). Statin use has been demonstrated to decrease the incidence of stroke by reducing atherosclerotic plaque burden. However, its effect on the hemodynamic situation and cerebral perfusion status has not yet been validated. With the use of computed tomography perfusion (CTP), we aim to evaluate the impact of Rosuvastatin on cerebral hemodynamic changes, as well as the downstream perfusion.Method: Cerebral bood flow evaluation of intensive rosuvastatin therapy in patients with intracranial arterial atherosclerotic stenosis (CEIRIS) is a single‐center, prospective, randomized, parallel‐group, and open‐label trial, and it will include 50 participants as estimated. Patients with moderate to severe (50%–99%) ICAS are randomized 1:1 to 10 mg/day or 20 mg/day Rosuvastatin and followed every 13 weeks until 52 weeks. The primary outcome for the trial is the change in the relative regional cerebral blood flow evaluated by CTP after 52 weeks of Rosuvastatin treatment. The secondary outcomes are cerebral blood volume, change in the degree of stenosis of the target vessel and lipid parameters.Conclusion: The CEIRIS trial about the effects of statin on the temporal hemodynamic progression of ICAS may extend our understanding of the basic pathophysiology and mechanisms of stroke in ICAS patients.
- Open Access
- 17 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 59810-59822
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
- 17 March 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (35) , 59810-59822
Open AccessEfficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective study
- 1 May 2016
- Vol. 41 (5) , 513-519
[Effect of pre-transplant donor specific antibody on antibody-mediated rejection and graft dysfunction].
To explore the effect of pre-transplant donor specific antibody (DSA) on antibody-mediated rejection (AMR) and function of transplanted kidney. A total of 88 cases of renal transplant recipients were selected. Before surgery, DSA was examined by Luminex liquid phase chip in renal transplant recipients. The recipients were divided into a DSA positive group (n=20) and a DSA negative group (n=68). The follow-up time was 2 years. After the operation, the pathologic morphology of the transplanted kidney was evaluated and classified according to the Banff 2005 standard. The situation for the transplanted kidney was evaluated. The incidence of AMR in the DSA positive group and negative group was 20% and 1.5%, respectively, with significant difference between them (P0.05). The detection of DSA level before renal transplantation can predict the risk of AMR and the function of transplanted kidney. The MFI intercept point of the highest DSA (MFI> 7909.5) can be used to predict the risk of AMR.
- 1 May 2016
- Vol. 41 (5) , 513-519
[Effect of pre-transplant donor specific antibody on antibody-mediated rejection and graft dysfunction].
To explore the effect of pre-transplant donor specific antibody (DSA) on antibody-mediated rejection (AMR) and function of transplanted kidney. A total of 88 cases of renal transplant recipients were selected. Before surgery, DSA was examined by Luminex liquid phase chip in renal transplant recipients. The recipients were divided into a DSA positive group (n=20) and a DSA negative group (n=68). The follow-up time was 2 years. After the operation, the pathologic morphology of the transplanted kidney was evaluated and classified according to the Banff 2005 standard. The situation for the transplanted kidney was evaluated. The incidence of AMR in the DSA positive group and negative group was 20% and 1.5%, respectively, with significant difference between them (P0.05). The detection of DSA level before renal transplantation can predict the risk of AMR and the function of transplanted kidney. The MFI intercept point of the highest DSA (MFI> 7909.5) can be used to predict the risk of AMR.